at Nasdaq.com (Tue, 2:51PM)
Merck (MRK +0.5%) gives a ray hope to its dwindling pipeline, after saying that Phase 2b studies of MK-3102, its investigational once-weekly treatment for Type 2 diabetes , significantly lowered blood sugar when compared with a placebo. The pharmaceutical giant presented the data at the annual meeting of the European Association for the Study of Diabetes in Berlin, noting the results were very encouraging and it plans to begin Phase 3 studies very soon.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Nasdaq.com (Mon, 12:38PM)
at Zacks.com (Jan 16, 2015)
at Zacks.com (Jan 15, 2015)
at Nasdaq.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs